Evaluating immunosuppressive agents for treating Thyroid Associated Ophthalmopathy
A Multi-model Image of Immunosuppressive Agents in Thyroid Associated Ophthalmopathy.
This study is testing if certain immune-suppressing medications can help people with Thyroid Associated Ophthalmopathy feel better and improve their vision.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 12 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Sun Yat-sen University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT05110040 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of immunosuppressive agents in treating Thyroid Associated Ophthalmopathy (TAO) using multi-modal imaging techniques. TAO is an autoimmune condition that leads to the enlargement of eye muscles and surrounding tissues, impacting both appearance and vision. The study aims to provide a more reliable and accurate assessment of treatment efficacy through advanced imaging and functional evaluations. By focusing on patients in the inactive phase of TAO, the study seeks to address the challenges of subjective measurement in current treatment assessments.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-70 diagnosed with Thyroid Associated Ophthalmopathy.
Not a fit: Patients with contraindications to immunosuppressive agents or significant active infections will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective treatment options for patients with Thyroid Associated Ophthalmopathy, improving their visual function and quality of life.
How similar studies have performed: While the use of multi-modal imaging in assessing TAO is relatively novel, similar approaches in other autoimmune conditions have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Informed consent * Age 18-70 years old * Diagnosed with TAO. Exclusion Criteria: * Contraindications to immunosuppressive agents. * Patients with HIV, Hepatitis B or C, Tuberculosis or other active significant infection. * Patients with severe chronic diseases in heart, lung, kidney and liver, which make it not tolerant to immunosuppressive agents. * Patients have contraindications of MRI(metal pacemaker, fake teeth, foreign body and other materials which will disturb the examination).
Where this trial is running
Guangzhou, Guangdong
- Zhongshan Ophthalmic Center — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Dan Liang — Zhongshan Ophthalmic Center, Sun Yat-sen University
- Study coordinator: Dan Liang
- Email: liangdan@gzzoc.com
- Phone: （86）-87330402
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.